Spatial Approximations between Residues 6 and 12 in the Amino-terminal Region of Glucagon-like Peptide 1 and Its Receptor

Understanding the molecular basis of natural ligand binding and activation of the glucagon-like peptide 1 (GLP1) receptor may facilitate the development of agonist drugs useful for the management of type 2 diabetes mellitus. We previously reported molecular approximations between carboxyl-terminal residues 24 and 35 within GLP1 and its receptor. In this work, we have focused on the amino-terminal region of GLP1, known to be critical for receptor activation. We developed two high-affinity, full agonist photolabile GLP1 probes having sites of covalent attachment in positions 6 and 12 of the 30-residue peptide (GLP1(7–36)). Both probes bound to the receptor specifically and covalently labeled single distinct sites. Chemical and protease cleavage of the labeled receptor identified the juxtamembrane region of its amino-terminal domain as the region of covalent attachment of the position 12 probe, whereas the region of labeling by the position 6 probe was localized to the first extracellular loop. Radiochemical sequencing identified receptor residue Tyr145, adjacent to the first transmembrane segment, as the site of labeling by the position 12 probe, and receptor residue Tyr205, within the first extracellular loop, as the site of labeling by the position 6 probe. These data provide support for a common mechanism for natural ligand binding and activation of family B G protein-coupled receptors. This region of interaction of peptide amino-terminal domains with the receptor may provide a pocket that can be targeted by small molecule agonists.

[1]  B. Wulff,et al.  Different domains of the glucagon and glucagon‐like peptide‐1 receptors provide the critical determinants of ligand selectivity , 2003, British journal of pharmacology.

[2]  G. Bitan,et al.  Photoaffinity Cross-linking Identifies Differences in the Interactions of an Agonist and an Antagonist with the Parathyroid Hormone/Parathyroid Hormone-related Protein Receptor* , 2000, The Journal of Biological Chemistry.

[3]  L. Miller,et al.  Demonstration of a Direct Interaction between Residue 22 in the Carboxyl-terminal Half of Secretin and the Amino-terminal Tail of the Secretin Receptor Using Photoaffinity Labeling* , 1999, The Journal of Biological Chemistry.

[4]  L. Suva,et al.  Direct mapping of an agonist-binding domain within the parathyroid hormone/parathyroid hormone-related protein receptor by photoaffinity crosslinking. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Chorev,et al.  Mapping the bimolecular interface of the parathyroid hormone (PTH)-PTH1 receptor complex: spatial proximity between Lys(27) (of the hormone principal binding domain) and leu(261) (of the first extracellular loop) of the human PTH1 receptor. , 2000, Biochemistry.

[6]  P. Hajduk,et al.  Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS , 2007, Proceedings of the National Academy of Sciences.

[7]  Byung-Kwon Lee,et al.  The mid-region of parathyroid hormone (1-34) serves as a functional docking domain in receptor activation. , 2006, Biochemistry.

[8]  R. Abagyan,et al.  Molecular Approximations between Residues 21 and 23 of Secretin and Its Receptor: Development of a Model for Peptide Docking with the Amino Terminus of the Secretin Receptor , 2007, Molecular Pharmacology.

[9]  A. Couvineau,et al.  The N-Terminal Parts of VIP and Antagonist PG97–269 Physically Interact with Different Regions of the Human VPAC1 Receptor , 2008, Journal of Molecular Neuroscience.

[10]  M. Beyermann,et al.  Photoaffinity cross-linking of the corticotropin-releasing factor receptor type 1 with photoreactive urocortin analogues. , 2005, Biochemistry.

[11]  L. Miller,et al.  Molecular Approximation between a Residue in the Amino-terminal Region of Calcitonin and the Third Extracellular Loop of the Class B G Protein-coupled Calcitonin Receptor* , 2004, Journal of Biological Chemistry.

[12]  L. Miller,et al.  Multiple Extracellular Loop Domains Contribute Critical Determinants for Agonist Binding and Activation of the Secretin Receptor* , 1996, The Journal of Biological Chemistry.

[13]  D. Drucker,et al.  International Union of Pharmacology. XXXV. The Glucagon Receptor Family , 2003, Pharmacological Reviews.

[14]  L. Miller,et al.  Critical Contributions of Amino-terminal Extracellular Domains in Agonist Binding and Activation of Secretin and Vasoactive Intestinal Polypeptide Receptors. STUDIES OF CHIMERIC RECEPTORS (*) , 1995, The Journal of Biological Chemistry.

[15]  R. Rudolph,et al.  Passing the baton in class B GPCRs: peptide hormone activation via helix induction? , 2009, Trends in biochemical sciences.

[16]  Laurence J Miller,et al.  Molecular Basis of Glucagon-like Peptide 1 Docking to Its Intact Receptor Studied with Carboxyl-terminal Photolabile Probes* , 2009, The Journal of Biological Chemistry.

[17]  R. Rudolph,et al.  In vitro folding, functional characterization, and disulfide pattern of the extracellular domain of human GLP-1 receptor. , 2002, Biophysical chemistry.

[18]  T. Lybrand,et al.  Direct Identification of a Distinct Site of Interaction between the Carboxyl-terminal Residue of Cholecystokinin and the Type A Cholecystokinin Receptor Using Photoaffinity Labeling* , 1997, The Journal of Biological Chemistry.

[19]  Toru Egashira,et al.  Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population. , 2004, Diabetes research and clinical practice.

[20]  Lotte Bjerre Knudsen,et al.  Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor* , 2009, The Journal of Biological Chemistry.

[21]  D. Drucker,et al.  Glucagon and glucagon-like peptide receptors as drug targets. , 2006, Current pharmaceutical design.

[22]  H. Jüppner,et al.  Multiple Sites of Contact between the Carboxyl-terminal Binding Domain of PTHrP-(1–36) Analogs and the Amino-terminal Extracellular Domain of the PTH/PTHrP Receptor Identified by Photoaffinity Cross-linking* , 2001, Journal of Biological Chemistry.

[23]  L. B. Knudsen,et al.  Structure-activity studies of glucagon-like peptide-1. , 1994, The Journal of biological chemistry.

[24]  L. Miller,et al.  Juxtamembranous Region of the Amino Terminus of the Family B G Protein-coupled Calcitonin Receptor Plays a Critical Role in Small-molecule Agonist Action* , 2009, The Journal of Biological Chemistry.

[25]  R. Abagyan,et al.  Spatial Approximation between Secretin Residue Five and the Third Extracellular Loop of Its Receptor Provides New Insight into the Molecular Basis of Natural Agonist Binding , 2008, Molecular Pharmacology.

[26]  L. Suva,et al.  Parathyroid Hormone-Receptor Interactions Identified Directly by Photocross-linking and Molecular Modeling Studies* , 1998, The Journal of Biological Chemistry.

[27]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[28]  M. Wheeler,et al.  Characterization of glucagon-like peptide-1 receptor-binding determinants. , 2000, Journal of molecular endocrinology.

[29]  A. Couvineau,et al.  Peptide Agonist Docking in the N-terminal Ectodomain of a Class II G Protein-coupled Receptor, the VPAC1 Receptor , 2006, Journal of Biological Chemistry.

[30]  L. Miller,et al.  Intrinsic photoaffinity labeling of native and recombinant rat pancreatic secretin receptors. , 1993, Gastroenterology.

[31]  R. Riek,et al.  Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand , 2007, Proceedings of the National Academy of Sciences.

[32]  D. Donnelly,et al.  The glucagon‐like peptide‐1 receptor binding site for the N‐terminus of GLP‐1 requires polarity at Asp198 rather than negative charge , 2002, FEBS letters.

[33]  K. Eckart,et al.  Structure/activity characterization of glucagon-like peptide-1. , 1994, European journal of biochemistry.

[34]  T. Gardella,et al.  Identification of a contact site for residue 19 of parathyroid hormone (PTH) and PTH-related protein analogs in transmembrane domain two of the type 1 PTH receptor. , 2003, Molecular endocrinology.

[35]  A. Piserchio,et al.  Characterization of parathyroid hormone/receptor interactions: structure of the first extracellular loop. , 2000, Biochemistry.

[36]  Tsutomu Kouyama,et al.  Crystal structure of squid rhodopsin , 2008, Nature.

[37]  H. Xu,et al.  Molecular Recognition of Corticotropin-releasing Factor by Its G-protein-coupled Receptor CRFR1* , 2008, Journal of Biological Chemistry.

[38]  H. Xu,et al.  Molecular recognition of parathyroid hormone by its G protein-coupled receptor , 2008, Proceedings of the National Academy of Sciences.

[39]  R. Rudolph,et al.  The N-terminal fragment of human parathyroid hormone receptor 1 constitutes a hormone binding domain and reveals a distinct disulfide pattern. , 2000, Biochemistry.

[40]  L. Miller,et al.  Use of N,O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides. , 2009, International journal of peptide and protein research.

[41]  T. Lybrand,et al.  Spatial Approximation between the Amino Terminus of a Peptide Agonist and the Top of the Sixth Transmembrane Segment of the Secretin Receptor* , 2004, Journal of Biological Chemistry.

[42]  C. Strader,et al.  The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity. , 1996, Receptors & channels.

[43]  Renxiao Wang,et al.  Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists , 2009, Journal of molecular modeling.

[44]  S. Hoare,et al.  Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. , 2005, Drug discovery today.

[45]  L. Miller,et al.  Importance of the Amino Terminus in Secretin Family G Protein-coupled Receptors , 2004, Journal of Biological Chemistry.

[46]  A. Couvineau,et al.  Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production. , 1997, Biochemical and biophysical research communications.

[47]  A. Kopin,et al.  A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness , 2005, Regulatory Peptides.

[48]  Y. Cao,et al.  The amino-terminal fragment of the adenylate cyclase activating polypeptide (PACAP) receptor functions as a high affinity PACAP binding domain. , 1995, Biochemical and biophysical research communications.

[49]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[50]  A. Couvineau,et al.  The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics. , 2008, Molecular endocrinology.

[51]  Kjeld Madsen,et al.  Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain* , 2008, Journal of Biological Chemistry.

[52]  L. Miller,et al.  Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors. , 2008, Molecular endocrinology.

[53]  J. Vilardaga,et al.  The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors , 1996, Peptides.

[54]  L. Miller,et al.  Relationship Between Native and Recombinant Cholecystokinin Receptors: Role of Differential Glycosylation , 1996, Pancreas.

[55]  D. Drucker Biologic actions and therapeutic potential of the proglucagon-derived peptides , 2005, Nature Clinical Practice Endocrinology &Metabolism.

[56]  R. Riek,et al.  NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[57]  D. Donnelly,et al.  Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues. , 2004, Protein and peptide letters.

[58]  Angela Wittelsberger,et al.  Mapping peptide hormone-receptor interactions using a disulfide-trapping approach. , 2008, Biochemistry.